Purpose: We developed a new technique to fold a neobladder (NB) simply by using a modified Vesica Ileale Padovana (VIP) with a hybrid approach. We provide a step-by-step description of our technique as it was used in this initial experience. Methods: A total of 10 male patients with a median age of 66 years underwent robot-assisted radical cystectomy (RARC) with an orthotopic NB via a hybrid approach from March 2022 to February 2023. After the isolation of the bladder and bilateral pelvic lymphadenectomy, Wallace plate creation was performed, and the robot was undocked. We extracorporeally performed the removal of the specimen and a side-to-side ileoileal anastomosis, and then the VIP NB posterior plate was rotated 90 degrees counterclockwise using a 45 cm detubularized ileum. The robot was redocked; then, circumferential urethra–ileal anastomosis, side-to-middle anterior wall closure, and ureteric afferent limb anastomosis were performed. Results: The median estimated blood loss was 524 mL, and the mean operative time was 496 min. Patients had a high continence rate, and no high-grade complications were observed. Conclusion: The NB configuration using the modified VIP method for a hybrid approach is a feasible surgical technique to minimize the movement of robotic forceps. In particular, it may be more useful in Asian individuals with narrow pelvises.

We report using the checkpoint inhibitor, pembrolizumab, as part of a multimodal treatment plan in a 36-year-old man with a rare bladder cancer arising 25 years after augmentation cystoplasty (sigmoid colonic cystectomy for neuropathic bladder was performed at 9 years old). On a regular clinic visit for clean intermittent catheterisation, the patient presented with gross haematuria and was diagnosed with urothelial carcinoma with sarcomatoid change. Gemcitabine and cisplatin-based neoadjuvant chemotherapy was unsuccessful, and pembrolizumab infusions (200 mg every 3 weeks) were initiated. A partial response was confirmed after six courses of pembrolizumab, with significant tumour shrinkage. A radical cystoprostatectomy and ileal conduit construction was performed, and pathology revealed no evidence of malignancy (ypT0, N0). The patient was successfully treated with the anti-programmed death-1 inhibitor, pembrolizumab, which was curative after total cystectomy. Further research is required to elucidate the potential role of checkpoint inhibitors in bladder cancers arising after augmentation cystoplasty.

Objectives: The enhanced recovery after surgery (ERAS) protocol is a coordinated approach aimed at providing the best evidence-based perioperative care. This study examined whether combining robot-assisted radical cystectomy (RARC) with the ERAS protocol could reduce postoperative complications and hospital length of stay (LOS). We also assessed the impact of high and low adherence to the ERAS protocol on oncological outcomes. Methods: Eighty patients who underwent RARC with urinary diversion at Juntendo University Hospital and Juntendo University Nerima Hospital between April 2014 and December 2021 were included. The ERAS protocol consisted of 15 items, and the achievement rate for each item was assessed. We evaluated the effects of adherence on complications and hospital LOS, as well as the relationship between ERAS implementation and postoperative oncological prognoses. Results: Patients were divided into high-adherence (n = 39) and low-adherence (n = 41) groups based on adherence to 12 or more ERAS items. Patient demographics, including age, sex, and clinical stage, were statistically similar. The high-adherence group had a significantly shorter postoperative hospital LOS (19 days vs. 24 days; p = 0.013) and fewer complications (p = 0.015) compared to the low-adherence group. Furthermore, the high-adherence group exhibited a significantly improved overall survival rate (p = 0.029), while no significant difference was found in progression-free survival (p = 0.125). Conclusions: Integrating the ERAS protocol with RARC can reduce postoperative complications and hospital LOS. High adherence to the ERAS protocol is associated with improved prognoses and outcomes compared to low adherence.

We report using the programmed death-1 immune checkpoint inhibitor (ICI) antibody, nivolumab, as part of a multimodal treatment strategy in small cell bladder carcinoma (SCBC). The patient presented with gross haematuria and was diagnosed with urothelial carcinoma with SCBC. He received neoadjuvant chemotherapy (NAC; carboplatin plus etoposide) according to the small cell lung cancer regimen. After three cycles of NAC, there was no progression of local disease, and a robot-assisted radical cystectomy with ileal conduit was conducted. Post surgery, the patient was treated with nivolumab (240 mg) every 2 weeks as a maintenance therapy after adjuvant cisplatin plus etoposide therapy. After more than 1.5 years post surgery, no tumour recurrence or metastases are present. The patient was treated with nivolumab, which was curative after radical cystectomy. Further research is required to elucidate the potential role of ICIs in SCBC.

Background: Cisplatin‐based chemotherapy is the standard treatment for metastatic seminoma but may be unsuitable for elderly patients with comorbidities. We report a case of metastatic seminoma with chronic kidney disease (CKD) in an elderly patient successfully treated with carboplatin monotherapy. Case Presentation: A 70‐year‐old man presented with a left testicular tumor and para‐aortic lymphadenopathy, causing left‐sided hydronephrosis. Radical left high orchiectomy confirmed stage IIC pure seminoma pT1N3M0 with a favorable prognosis according to the International Germ Cell Cancer Collaborative Group classification. Because renal impairment and poor performance status precluded cisplatin‐based chemotherapy, the patient received four cycles of carboplatin monotherapy (AUC 7). Grade 2–3 pancytopenia occurred but was manageable with pegfilgrastim and dose interval adjustment. Post‐treatment PET‐CT showed no residual uptake. Consolidation para‐aortic radiotherapy was subsequently performed. The patient remains disease‐free 1.5 years after treatment. Conclusion: Carboplatin monotherapy may be a feasible alternative for metastatic seminoma patients who are unsuitable for cisplatin‐based chemotherapy.